SNWV at a glance
SANUWAVE Health, Inc. (SNWV, SEC CIK 1417663) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SANUWAVE Health, Inc. (SNWV) reported revenue of $44.1 million (up 35.0% from FY2024) and net income of $11.8 million. Diluted EPS was $0.41.
- As of September 30, 2026, 13 institutional investment managers tracked by SignalX reported holding SANUWAVE Health, Inc. (SNWV) shares worth $3.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $44.1M
- +35.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 13 funds
- $3.7M · −1 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $8.6M, down 24% YoY from $11.3M
- Gross margin 77% vs 78% YoY, operating loss $1.1M vs operating income $0.9M
- Worst performer Ultramist® systems: $1.2M, down 73% from $4.4M
- Cash $6.6M, operating cash outflow $29K, financing outflow $4.6M
- Near-term headwinds: weaker capital sales, used-system availability, Nasdaq MVLS compliance by March 22, 2027
Risk Factors
- Newly added covenant risk: JPM Credit Agreement breach as of September 30, 2026, waived under October 28 amendment
- Reimbursement risk: CPT 97610 Medicare payment falling to $314.54 in 2027 from $397.81 in 2026
- Regulatory risk: CMS estimates skin-substitute reimbursement changes reduce Medicare spending nearly 90%
- Market risk: Customer reimbursement pressure contributed to deferred or reduced capital purchases during 2026
- Nasdaq compliance risk: MVLS below $50.0 million threshold, with compliance deadline March 22, 2027
AI summary of the SNWV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Business update conference call scheduled November 11, 2026 at 8:30 a.m. EST
Item EX-99.1: Item EX-99.1
- Q3 revenue $8.6M, down 24% from $11.3M, reflecting sharply weaker Ultramist system demand
- Ultramist systems sold fell to 40 from 155, while applicator revenue increased 2% to $6.9M, highlighting recurring-revenue resilience
Item 1.01: Entry into a Material Definitive Agreement
- Lenders waived fixed-charge coverage default risk for the twelve months ending September 30, 2026
- Written lender consent now required for permitted acquisitions and certain equity repurchases
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq MVLS below $50 million for 30 consecutive business days, triggering a continued-listing deficiency
- Common stock remains listed on Nasdaq Global Market with no immediate delisting
AI summaries of SNWV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SNWV
Don't miss the next SNWV filing
- Alerts as it files. A push when SNWV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SNWV, by share count.
- Ask anything. An AI agent that reads every SNWV filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Miller Ian D. | A | Sep 30, 2026 | 12,697 | - |
| Bazar Gregory Matthew | A | Sep 30, 2026 | 11,286 | - |
| Tyler James | A | Sep 30, 2026 | 11,286 | - |
| FRANK MORGAN C. | A | Sep 30, 2026 | 11,286 | - |
| Blizard Jeffrey | A | Sep 30, 2026 | 11,286 | - |
| Bazar Gregory Matthew | A | Jun 30, 2026 | 5,524 | - |
| Blizard Jeffrey | A | Jun 30, 2026 | 5,524 | - |
| Tyler James | A | Jun 30, 2026 | 5,524 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $32.6M | $44.1M |
| Gross Profit | - | $24.6M | $34.0M |
| Operating Income | - | $5.4M | $4.9M |
| Net Income | - | -$31.4M | $11.8M |
| Gross Margin | - | 75.2% | 77.1% |
| Op. Margin | - | 16.6% | 11.2% |
| Net Margin | - | -96.1% | 26.8% |
| Balance Sheet | |||
| Total Assets | - | $30.1M | $37.3M |
| Equity | -$44.5M | -$12.7M | $1.6M |
| ROE | - | 246.7% | 729.6% |
| Per Share | |||
| EPS | - | $-7.03 | $0.41 |
| Cash Flow | |||
| Operating CF | - | $2.5M | $3.9M |
| CapEx | $0 | $490K | $1.9M |
Source: XBRL data in SANUWAVE Health, Inc. (SNWV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SNWV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 13 | $3.7M |
| Q2 2026 | 14 | $7.9M |
| Q1 2026 | 16 | $21.0M |
| Q4 2025 | 14 | $36.8M |
| Q3 2025 | 14 | $46.9M |
| Q2 2025 | 13 | $33.2M |
| Q1 2025 | 6 | $10.9M |
- JPMorgan Chase & Co+10.4K (+26%)
- Bank of America Corp+11 (+0%)
- Citadel Advisors LLC−36.4K (-61%)
- BlackRock−16.9K (-11%)
- Goldman Sachs Group−15.8K (-39%)
- Millennium Management−6.6K (-39%)
- Vanguard Capital Management LLC−4.7K (-1%)
- D.E. Shaw & Co+59.3K
- Invesco Ltd+25.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 90 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SNWV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 4, 2026 | - | - | - |
| 4 | Apr 30, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SNWV SEC filings: frequently asked questions
Which institutions hold SNWV stock?
As of September 30, 2026, the largest SANUWAVE Health, Inc. (SNWV) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.6 million), BlackRock ($673,000), D.E. Shaw & Co ($279,000), JPMorgan Chase & Co ($238,000), State Street Corp ($147,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SNWV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SANUWAVE Health, Inc. (SNWV) reported revenue of $44.1 million (up 35.0% from FY2024) and net income of $11.8 million. Diluted EPS was $0.41. The figures come from the XBRL data in the 10-K.
What did SNWV report in its latest 8-K?
SANUWAVE Health, Inc. (SNWV) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest SNWV SEC filings?
SANUWAVE Health, Inc. (SNWV) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 2, 2026.
What is SNWV's SEC CIK number?
SANUWAVE Health, Inc. (SNWV)'s SEC Central Index Key (CIK) is 1417663. EDGAR lists every SNWV filing under that number.
Ask anything about SNWV
The research agent reads SNWV's filings, financials, insider trades and 13F holders, then answers with sources.